ctDNA can be a powerful tool to detect relapse before radiographic PD. Terrific presentation by A/Prof Tom John ASCO #ASCO24 MRD+ detected relapse 4.7 month earlier, and further work needs to be done to select the pts for escalation of tx #LCSM OncoAlert

Dr. Tina Cascone gives an important update on CheckMate 77T at the #ASCO24 oral abstract session. CheckMate 77T was a phase III study showing the addition of perioperative nivolumab to neoadjuvant chemo for resectable stage II/III NSCLC improved both EFS & pCR. Here, N2+ subset.

donington discussion of CM77T; brilliant analysis describing the outcomes in N2 and specifically multistation N2; concluding resectability is about bulk and invasiveness, not number of stations. #ASCO24

We hope to see you during Black Family Cancer Awareness Week for a conversation with Dr. Marcus Noel! On Thursday, June 27, 2024 at 11 a.m. PT/2 p.m. ET, he'll be answering your questions about #pancreaticcancer, with a special focus on the disparities experienced by the Black

Bittersweet day Georgetown Lombardi as Dr. Jennifer Marks, MD has her last thoracic clinic with me! All of our patients (and I) will sorely miss her but we wish her the best Dana-Farber as she takes her next step!

Congratulations Jennifer Marks, MD and best of luck as you begin your career at Dana-Farber! Looking forward to continuing to see your meteoric rise as a leader in the field!!

Such a sad day for the EGFR Resisters and greater lung cancer & #LCSM community. Ivy Elkins was such a fierce patient advocate and incredibly kind soul. My heart goes out to her family and everyone she touched along her journey battling this devastating disease.

It is with great sadness that we say good-bye to our dear friend and powerful lung cancer advocate, Ivy Elkins. We will remember Ivy as vibrant, compassionate, and unselfish; never defined by her cancer, and always proving that she was a person, not a statistic.

A large amt of data has emerged on multiple promising ADCs for lung cancer in recent months, with several agents on the precipice of approval. For a concise & comprehensive review of ADCs, see our latest review in Clin Adv Hem Onc. Benjamin Levy Samuel Rosner

Congratulations to my dear friend Ana I. Velázquez Mañana, MD, MSc, FASCO on becoming one of the youngest FASCO designees!!! A reflection of her remarkable dedication to ASCO through leadership, advocacy, mentorship, & Conquer Cancer, the ASCO Foundation-funded research! Proud to serve ASCO alongside you & many other

#ILCN remembers Ivy B. Elkins, 1966-2024: "Lung cancer has taken yet another bright light from our world—a beautiful soul. However, it can never take away Ivy Elkins' impact on countless lives." bit.ly/3zCALhK #LCSM

Dr. Tina Cascone from MD Anderson Cancer Center will offer her insights on neoadjuvant and perioperative immunotherapy for early stage NSCLC at #DCLung24. Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Dr. Christine Lovly, MD, PhD will help us better understand biomarker testing in lung cancer at #DCLung24. Don't miss this important update! Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Dr. Marina Garassino takes center stage at #DCLung24 to debate Joshua Reuss on the role of adjuvant chemotherapy when adjuvant #ALK TKI is planned. Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Dr. Chul Kim from Georgetown Lombardi will discuss advances in treating lung cancer with an #EGFR exon 20 or a #HER2 exon 20 mutation at #DCLung24. Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Durva + Chemo now approved based off #AEGEAN: PeriOp Durva + NeoAdj Chemo -> ✂️ -> 1yr Durva, IIA-IIIB (N2) NSCLC. - PeriOp IO/Chemo improves pCR 17.2% Vs. 4.3% - Improved EFS (also seen in #CM816). HR: 0.68 - KN671, CM816, and now AEGEAN (awaiting CM77T) #lcsm #OncTwitter

What a 🌟 lineup at #DCLung24! Can't wait to reconnect with so many colleagues and friends from across the continent (that's right 🇨🇦 represented here too!) in our great city.

Dr. Charu Aggarwal, MD, MPH, FASCO will discuss some of the critical updates in unresectable stage III NSCLC at #DCLung24 including PACIFIC(2) and LAURA. Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Dr. Joshua Reuss takes center stage at #DCLung24 to debate Marina Garassino on the role of adjuvant chemotherapy when adjuvant #ALK TKI is planned. Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Our #METworking paper in collaboration with Caris Life Sciences now in Lung Cancer Journal #lcsm METCrusaders - METex14+ nSq have improved OS vs Sq - METex14 + receiving IO have improved OS compared to those who did not receive IO - POT1 enriched independent of histology -⬇️ prevalence